Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP:RHHBF)

343.56 -6.44 (-1.84%)
Streaming Delayed Price Updated: 11:07 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 7 Next >
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
 
Via Benzinga
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
 
Via Benzinga
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
 
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
 
Via Benzinga
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
 
Via Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
 
Via Benzinga
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
 
Via Benzinga
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
 
Via Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
 
Via Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
 
Via Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
 
Via Benzinga
Roche's Follicular Lymphoma Therapy Scores FDA Approval
 
Via Benzinga
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
 
Via Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
 
Via Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
 
Via Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
 
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
 
Via Benzinga
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
 
Via Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
 
Via Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
 
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
 
Via Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
 
Via Benzinga
Why Is Hookipa (HOOK) Stock Up 26% Today?
Hookipa (HOOK) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (RHHBF). 
Via InvestorPlace
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
 
Via Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
 
Via Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
 
Via Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
 
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.